60 Degrees Pharmaceuticals Secures Option for Castanospermine in Tick-Borne Diseases — 60 Degrees Pharmaceuticals, Inc.

Event summary

60 Degrees Pharmaceuticals has entered an exclusive option agreement with Florida State University to license castanospermine for tick-borne diseases, including Powassan virus disease and alpha-gal syndrome.
The deal covers patented technology and know-how related to the therapeutic development of castanospermine in the U.S.
Castanospermine, a naturally occurring iminosugar, has shown broad antiviral and immunomodulatory activity in preclinical studies.
The company is re-evaluating its regulatory strategy for dietary supplements while prioritizing prescription drug development.

The big picture

This agreement underscores 60 Degrees Pharmaceuticals' strategic pivot toward prescription drugs for tick-borne diseases, aligning with broader industry trends of targeting underserved infectious disease markets. The deal builds on the company's existing expertise in vector-borne diseases and complements its ongoing development of tafenoquine for babesiosis.

What we're watching

Regulatory Strategy: How the company's shift in focus from dietary supplements to prescription drugs will impact its development timeline and commercialization strategy.
Clinical Development: The pace at which 60 Degrees Pharma can advance castanospermine through clinical trials for multiple tick-borne diseases.
Market Positioning: Whether the company can leverage its expertise in vector-borne diseases to establish a strong market presence in tick-borne disease treatments.